Elacestrant for advanced ER+/HER2- breast cancer with ESR1 mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral drug called elacestrant in women whose ER+/HER2- breast cancer has worsened after at least one hormone therapy. It is for those with a specific genetic change (ESR1 mutation) and advanced or metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You are postmenopausal (either from surgery, age over 60, or other hormonal changes)
- You have ER-positive and HER2-negative breast cancer that is advanced or has spread
- Your tumor has an ESR1 mutation
- Your cancer has gotten worse after at least one hormone treatment (like tamoxifen or an aromatase inhibitor)
- You are not pregnant or breastfeeding, and can swallow oral medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Hear when a new ESR1 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.